Resultados de Búsqueda por Autor

1

artículo

Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survi...

Publicado por
Gómez, Henry L., Samanéz, César, Campana, Frank, Neciosup, Silvia P., Vera, Luis, Casanova, Luis, Leon, Jorge, Flores, Claudio, Hurtado de Mendoza, Fernando, Casteñeda, Carlos A., Pinto, Joseph A., Vallejos, Carlos S.

Publicado 2012

Enlace

Se presenta el seguimiento a 8 años de 34 pacientes de edad mayor o igual a 69 años con Linfoma no Hodgkin, incluidos en un estudio de grupos paralelos aleatorios abiertos de fase IIb, para evaluar la efectividad de la amifostina en la prevención de la toxicidad de ciclofosfamida, doxorubicina, vincristina y prednisona (régimen CHOP). Los pacientes recibieron aleatoriamente CHOP clásico (ciclofosfamida 750 mg/m2, doxorubicina 50 mg/m2, vincristina 1,4 mg / m2 [máximo 2 mg] en el día 1 y prednisona 100 mg/día durante 5 días) o CHOP más amifostina (6 ciclos de amifostina 910 mg / m2 en el día 1). Se evaluó la eficacia (tiempo de progresión, supervivencia libre de enfermedad y sobrevivencia promedio) y parámetros de toxicidad.

2

artículo

Lung Cancer in Peru

Publicado por
Ruiz, Rossana, Galvez-Nino, Marco, Poquioma, Ebert, Limache-García, Abel, Amorin, Edgar, Olivera, Mivael, Valdiviezo, Natalia, Trejo, Juan M., Heredia, Adela, Sarria, Gustavo, Aguilar, Alfredo, Raez, Luis, Neciosup, Silvia P., Gomez, Henry L., Payet, Eduardo, Mas, Luis

Publicado 2020

Enlace

Peru is a South American nation with a growing and aging population of 31 million people with a life expectancy at birth of 76.7 years. The country is divided into 25 regions, 79% of the population is urban, and Lima, the capital, concentrates more than a third of the population.1 Although Peru is an upper-middle-income country, health expenditure represents only 5.1% of the gross domestic product, which is lower than the average of Latin America and the Caribbean (LATAM) (8.56%).2 Out-of-pocket health expenditure is 30.9%.3 Peru has a comprehensive National Cancer Plan and two population-based cancer registries in Lima and Arequipa.

3

artículo

Diagnóstico y tratamiento del cáncer de mama HER2+: Guía de Práctica Clínica de la Sociedad Peruana de Cancerología

Publicado por
Morante, Zaida D., Rebaza, Lia P., Castañeda, Carlos A., Luyo, Gustavo D., Neciosup, Silvia P., Vera, Luis A., Aliaga, Rolig A., Aliaga, Karina M., Cotrina, José M., Guerra, Rolando H., Fuentes, Hugo A., Malca, Jenny, Ballón, Karinthia, Fuentes Rivera, Paola, Negreiros, Tatiana, Mendoza, Zulma K., Hijar, Gisely, Aramburu, Adolfo, Gómez, Henry L.

Publicado 2021

Enlace

Introduction. In Peru, breast cancer represents the most common type of cancer in women and the sixth most lethal type of cancer in the general population. Overexpression of the epidermal growth factor receptor (HER2 +) occurs in 20% to 30% of breast cancers, and is associated with more aggressive tumors, with greater recurrence and greater mortality. Objective. Prepare a set of evidence-based recommendations for the diagnosis and treatment of HER2 + breast cancer, in order to help reduce mortality, disease progression and improve quality of life. Methods. A panel of clinical specialists and methodologists was formed, who identified relevant clinical questions about the diagnosis and treatment of HER2 + breast cancer. A systematic search for CPGs was carried out in Medline (PubMed), and in developing and compiling agencies. For the formulation of recomm...

4

artículo

Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women

Publicado por
Zavala, Valentina A., Casavilca-Zambrano, Sandro, Navarro-Vásquez, Jeannie, Castañeda, Carlos A., Valencia, Guillermo, Morante, Zaida, Calderón, Monica, Abugattas, Julio E., Gómez, Henry, Fuentes, Hugo A., Liendo-Picoaga, Ruddy, Cotrina, Jose M., Monge, Claudia, Neciosup, Silvia P., Huntsman, Scott, Hu, Donglei, Sánchez, Sixto E., Williams, Michelle A., Núñez-Marrero, Angel, Godoy, Lenin, Hechmer, Aaron, Olshen, Adam B., Dutil, Julie, Ziv, Elad, Zabaleta, Jovanny, Gelaye, Bizu, Vásquez, Jule, Gálvez-Nino, Marco, Enriquez-Vera, Daniel, Vidaurre, Tatiana, Fejerman, Laura

Publicado 2022

Enlace

Background: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/ Black or Non-Hispanic White women. An Indigenous American breast cancer-protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall ...